Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series.
Smith JL, Menzies AM, Cohen JV, Mut-Lloret M, Ozgun A, Spain L, Park J, Quach HT, Pallan L, McQuade J, Feng S, Sandhu S, Atkinson V, Tsai K, Long GV, Larkin J, Eroglu Z, Johnson DB, Sullivan R, Herkes GK, Henderson A, Carlino MS. Smith JL, et al. Among authors: quach ht. Melanoma Res. 2022 Dec 1;32(6):451-459. doi: 10.1097/CMR.0000000000000825. Epub 2022 Sep 23. Melanoma Res. 2022. PMID: 36164923
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy.
Bai X, Hu J, Betof Warner A, Quach HT, Cann CG, Zhang MZ, Si L, Tang B, Cui C, Yang X, Wei X, Pallan L, Harvey C, Manos MP, Ouyang O, Kim MS, Kasumova G, Cohen JV, Lawrence DP, Freedman C, Fadden RM, Rubin KM, Sharova T, Frederick DT, Flaherty KT, Rahma OE, Long GV, Menzies AM, Guo J, Shoushtari AN, Johnson DB, Sullivan RJ, Boland GM. Bai X, et al. Among authors: quach ht. Clin Cancer Res. 2021 Nov 1;27(21):5993-6000. doi: 10.1158/1078-0432.CCR-21-1283. Epub 2021 Aug 10. Clin Cancer Res. 2021. PMID: 34376536 Free PMC article.
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study.
Bai X, Shoushtari AN, Betof Warner A, Si L, Tang B, Cui C, Yang X, Wei X, Quach HT, Cann CG, Zhang MZ, Pallan L, Harvey C, Kim MS, Kasumova G, Sharova T, Cohen JV, Lawrence DP, Freedman C, Fadden RM, Rubin KM, Frederick DT, Flaherty KT, Long GV, Menzies AM, Sullivan RJ, Boland GM, Johnson DB, Guo J. Bai X, et al. Among authors: quach ht. Br J Dermatol. 2022 Sep;187(3):401-410. doi: 10.1111/bjd.21241. Epub 2022 May 20. Br J Dermatol. 2022. PMID: 35293617
Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.
Patrinely JR Jr, Young AC, Quach H, Williams GR, Ye F, Fan R, Horn L, Beckermann KE, Gillaspie EA, Sosman JA, Friedman DL, Moslehi JJ, Johnson DB. Patrinely JR Jr, et al. Eur J Cancer. 2020 Aug;135:211-220. doi: 10.1016/j.ejca.2020.05.005. Epub 2020 Jun 27. Eur J Cancer. 2020. PMID: 32599411 Free PMC article.
46 results